Arrow Pharmaceuticals to Float IPO | Appoints Global IME Capital as Issue Manager
April 13, 2025 | Investopaper
Arrow Pharmaceuticals Limited is in the process of issuing shares to the public (IPO). For this purpose, the company has appointed Global IME Capital Limited as the issue and sales manager.
The agreement for public offering was signed between the company and Global IME Capital Limited on this regard. The signing ceremony took place at Global IME Capital’s office in Naxal, where Uddav Prasad Mainali, Chairman of the Arrow Pharmaceuticals, and Mandeep Luitel, Chief Executive Officer of Global IME Capital, formalized the agreement.
Now, the company needs to submit the application to the Securities Board Of Nepal (SEBON). If approved by SEBON, the hydropower can issue the shares to the public.
In the first phase, the company will sell shares to the foreign employed Nepalis. Likewise, in the second phase, the company will float shares to the general public, including the employees of the company and the mutual fund schemes.
In total, the company plans to sell 15 lakh shares in the IPO. At a par value of Rs. 100, the public issue amounts to Rs. 15 crores.
About Arrow Pharmaceuticals Limited
Arrow Pharmaceuticals Limited is a pharmaceutical manufacturing and marketing company. The manufacturing plant is at Bhaktapur.
Recommended:
